-
-
-
-
-
-
-
Immunovant, Inc. (IMVT) Misses Q1 EPS by 1c
-
-
-
-
-
-
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Immunovant (IMVT) at Overweight, 'Don't Let IMVT be the One That Got Away'
-
-
-
-
-
-
-
Immunovant (IMVT) Reaches Agreement with FDA on Plans for Phase 3 Clinical Trials of Batoclimab
-
-
-
-
-
-
-
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021
-
-
-
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

